Online inquiry

IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ9491MR)

This product GTTS-WQ9491MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Chimeric
RefSeq	NM_001346897.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	1956
UniProt ID	Q504U8

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9491MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ10913MR	IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MABT5102A
GTTS-WQ6497MR	IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CX-072
GTTS-WQ14204MR	IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	RG4934
GTTS-WQ4906MR	IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	BYM338
GTTS-WQ15625MR	IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	VAY-736
GTTS-WQ1306MR	IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	ABT-555
GTTS-WQ10284MR	IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	LGT209
GTTS-WQ9697MR	IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	JNJ-64304500

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST